Peripheral neuropathy associated with ipilimumab: a report of 2 cases. uri icon

Overview

abstract

  • Ipilimumab, a monoclonal antibody targeting human cytotoxic T-lymphocyte-associated antigen 4, was approved by the FDA and European Medicines Agency for the treatment of metastatic melanoma. Immune-related adverse effects can occur with the use of this agent, but peripheral nervous system problems are rare. We report 2 cases of ipilimumab-induced polyneuropathy.

publication date

  • January 1, 2015

Research

keywords

  • Antibodies, Monoclonal
  • Chemical and Drug Induced Liver Injury
  • Head and Neck Neoplasms
  • Lung Neoplasms
  • Melanoma
  • Peripheral Nervous System Diseases
  • Skin Neoplasms

Identity

PubMed Central ID

  • PMC5628623

Scopus Document Identifier

  • 84922738416

Digital Object Identifier (DOI)

  • 10.1097/CJI.0000000000000070

PubMed ID

  • 25658617

Additional Document Info

volume

  • 38

issue

  • 2